by | May 14, 2025 | Oh, Youngmi, Yoo, Andrew
— Published Date: 5/14/2025
Value Proposition: Novel antisense oligonucleotide (ASO) directly targeting a microRNA-mediated mechanism responsible for autophagy reduction and neurodegeneration in Huntington’s disease (HD) improving patient outcomes in pre-HD subjects.
Technology Description
R…
by | May 13, 2025 | Haller, Gabriel, Li, Chengcheng, Weihl, Conrad
— Published Date: 5/14/2025
Value Proposition: Method that uses gene-therapy to detect limb-girdle muscular dystrophy (LGMD) type 4R/2E.
Technology Description
Researchers at Washington University in St. Louis have developed a method of predicting limb-girdle muscular dystrophy (LGMD) type 4R/2…
by | May 13, 2025 | Cavalli, Valeria, Feng, Rui
— Published Date: 12/21/24
Value proposition: A cost-effective, drug-based therapy targeting the endothelin B receptor (ETBR) to promote peripheral nerve regeneration, offering improved recovery and compatibility with existing treatments.
Technology Description
Researchers at Washington University…
by | May 12, 2025 | Singh, Nathan
— Published Date: 12/24/2024
Value proposition: An advanced CAR-T cell therapy engineered to reduce T cell exhaustion, enhancing durability and effectiveness in cancer treatment by overcoming one of the leading causes of long-term treatment failure.
Technology Description
Researchers at Washington…
by | Mar 6, 2025 | Cooper, Matthew, DiPersio, John
— Value Proposition: Engineered iNKT cells with potential as a “universal” source of immune effector cells to treat cancer.
Technology Description
Researchers at Washington University in St. Louis have developed a new composition of matter that uses gene-edited invariant natural kill…